Skip to main content
. 2022 Feb 3;30(4):398–406. doi: 10.1016/j.jsps.2022.01.022

Table 3.

Multivariate regression analysis for follow-up outcomes.

Outcomes Crude Analysis
P value Hazard Ratio (95 %CI) P value $
Standard dose Escalated dose
In-hospital mortality, n/N(%) Δ 64/173 (37.0) 65/171 (38.0) 0.85^^ 1.08 (0.76, 1.53) 0.67
30-day mortality, n/N(%) Δ 48/173 (27.7) 54/172 (31.4) 0.46^^ 1.17 (0.79, 1.73) 0.43
Beta- coefficient (95 %CI) P-value $*
ICU Length of Stay(Days), Median (Q1, Q3) & 9.0 (5.0,15.0) 8.0 (5.0,13.0) 0.39^ −0.12 (-0.31, 0.07) 0.23
Hospital Length of Stay(Days), Median (Q1, Q3) & 17.0 (11.0,24.0) 14.0 (10.0,24.0) 0.22^ −0.11 (-0.27, 0.06) 0.20
MV duration (Days), Median (Q1, Q3) & 6.0 (1.0, 13.0) 3.0 (0.0, 10.0) 0.29^ -0.17 (-0.58, 0.24) 0.41

Δ The Denominator is the total number of patients

& Denominator is the number of patients who survived.

^ Wilcoxon rank-sum test is used to calculate the P-value.

^^ Chi-square test is used to calculate the P-value.

$* Propensity score is used to calculate Beta- coefficient (estimate) and p-value.

$ Propensity score is used to calculate hazard ratio and p-value.